secwatch.observer — SEC 8-K summary
======================================

Issuer:     Drugs Made In America Acquisition Corp. (DMAA)
CIK:        0002028614
Form:       8-K
Filed at:   2025-11-18T23:59:59+00:00
Accession:  0001213900-25-111704
Event type: leadership
Sentiment:  neutral
Materiality: 0.40
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

CFO Glenn Worman resigns; Saleem Elmasri appointed as CFO of Drugs Made In America Acquisition Corp.
--------------------------------------------------------------------------------

- Glenn Worman resigned as CFO and principal financial & accounting officer on Oct 8, 2025; no disagreement cited.
- Saleem Elmasri appointed CFO effective Nov 17, 2025; will serve via Titan Advisory Services LLC.
- Elmasri receives $42,000/year ($3,500/month) consulting fee and 100,000 ordinary shares upon engagement.
- Elmasri is a CPA with 20 years experience, previously at PwC and as managing partner at Titan Advisory.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/2028614/000121390025111704/0001213900-25-111704-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/2028614/000121390025111704/ea0265998-8k_drugs.htm
  HTML page:      https://secwatch.observer/filing/0001213900-25-111704

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer